Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

2010 ◽  
Vol 15 (3-4) ◽  
pp. 88-97 ◽  
Author(s):  
Craig P. Carden ◽  
Debashis Sarker ◽  
Sophie Postel-Vinay ◽  
Timothy A. Yap ◽  
Gerthardt Attard ◽  
...  
Keyword(s):  
Drug Development ◽  
Phase I ◽  
Anticancer Drug ◽  
Patient Selection ◽  
Phase I Trials ◽  
Molecular Biomarker ◽  
Anticancer Drug Development

scholarly journals Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

2012 ◽  
Vol 23 (11) ◽  
pp. 2960-2963 ◽  
Author(s):  
A. Naing ◽  
H. Veasey-Rodrigues ◽  
D.S. Hong ◽  
S. Fu ◽  
G.S. Falchook ◽  
...  
Keyword(s):  
Drug Development ◽  
Phase I ◽  
Anticancer Drug ◽  
Cancer Center ◽  
Md Anderson ◽  
Anticancer Drug Development

Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development

2021 ◽  
Author(s):  
Abhijit Pal ◽  
Rajiv Shinde ◽  
Manuel Selvi Miralles ◽  
Paul Workman ◽  
Johann de Bono
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Liquid Biopsy ◽  
Audit Trail ◽  
Anticancer Drug Development

Non-invasive MRS in new anticancer drug development

1992 ◽  
Vol 5 (5) ◽  
pp. 270-272 ◽  
Author(s):  
Paul Workman ◽  
Ross J. Maxwell ◽  
John R. Griffiths
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Non Invasive ◽  
Anticancer Drug Development

Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development

2008 ◽  
Vol 44 (4) ◽  
pp. 494-500 ◽  
Author(s):  
Giuseppe Curigliano ◽  
Gianluca Spitaleri ◽  
Howard J. Fingert ◽  
Filippo de Braud ◽  
Cristiana Sessa ◽  
...  
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Qtc Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qtc Interval Prolongation ◽  
Anticancer Drug Development
Sign in / Sign up

Export Citation Format

Share Document